Kornimate/medical-research-clean huggingface dataset:
a study of baricitinib in participants with systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus

Summary: the reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (sle) who have completed the final treatment visit of study i4v-mc-jahz (nct03616912) or study i4v-mc-jaia (nct03616964).


Eligibility criteria:
inclusion criteria: * have completed the final treatment study visit of an originating study, such as study jahz (nct03616912) or study jaia (nct03616964).

Keywords: sle
what we think about the do-not-resuscitate order: survey study

Conditions: Knowledge, Attitudes, Practice

Summary: the do not resuscitate (dnr) order is a decision taken by the patient or other people about medical care in the end stages of life to withhold cpr in event of respiratory or cardiac arrest and allow natural death to occur. there is currently no related article of law to dnr order in turkey. it was aimed to evaluate the health workers(hw) and the non health workers'(nhw) knowledge, attitude, and behavior related to the do-not-resuscitate (dnr) order in turkey.

the do not resuscitate (dnr) order is a decision taken by the patient or other people about medical care in the end stages of life to withhold cpr in event of respiratory or cardiac arrest and allow natural death to occur. there is currently no related article of law to dnr order in turkey. a questionnaire with 25 questions has been distributed to health workers and non-health workers. it was aimed to evaluate the health workers(hw) and the non health workers'(nhw) knowledge, attitude, and behavior related to the do-not-resuscitate (dnr) order in turkey.

Eligibility criteria:
inclusion criteria: * adults ≥18 years of age * people who are able to complete the questionnaire exclusion criteria: -

Keywords: the do-not-resuscitate order, end of life, medical ethics
azacitidine combined with chidamide in the treatment of newly diagnosed ptcl unfit for conventional chemotherapy

Conditions: Peripheral T-cell Lymphoma

Summary: this prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral t-cell lymphoma unfit for conventional chemotherapy.

peripheral t-cell lymphoma (ptcl is a distinct and heterogeneous histopathologic subtype of non-hodgkin lymphoma (nhl), accounting for \~10%. chop regimen has been widely used in ptcl patients even with unfavourable prognosis, with 5-year overall survival rate of 38.5%. elderly patients seldom benefit from conventional chop regimen. a study showed that cr rate was only 18.1% in elderly patients (median age of 80 years old, ranging from 56 to 93 years old). azacitidine combined with romidepsin has been proved efficient in relasped or refractory ptcl, with cr rate of 55%. this prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral t-cell lymphoma unfit for conventional chemotherapy.

Eligibility criteria:
inclusion criteria: * pathologically confirmed peripheral t-cell lymphoma based on 2016 who classification * treatment naive * age ≥ 18 years * unfit for converntional chemotherapy meeting criteria as following but not limited to: age ≥75, ecog \>2，adl\ 1. * must has measurable lesion in ct or pet-ct prior to treatment * expected lifetime ≥ 3 months * informed consented exclusion criteria: * has accepted localized or systemic anti-lymphoma treatment * has accepted autologous stem cell transplantation before * history of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment * uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * primary cns lymphoma * left ef≤ 50% * lab at enrollment (unless caused by lymphoma): neutrophile\ 2\*uln; creatinine\>1.5\*uln * other uncontrollable medical condition that may that may interfere the participation of the study * not able to comply to the protocol for mental or other unknown reasons * patients with mentally disorders or other reasons unable to fully comply with the study protocol * pregnant or lactation * hiv infection * hbv-dna and hcv-rna undectable.

Keywords: peripheral t-cell lymphoma targeted therapy chemo-free therapy
the effect of music on preterm infant's brain development

Conditions: Prematurity

Summary: studying the effect of music intervention on preterm infants' brain development by mri and neurodevelopmental assessments


Eligibility criteria:
inclusion criteria: * preterm infants: 33 weeks \< gestational age \< 37 weeks * full-term newborns: 37 weeks gestational age \< 42 weeks exclusion criteria: * neurological issues or malformations (such as iii-iv stade intraventricular hemorrhage, micro or macrocephaly, hydrocephaly...) * because of the high noise caused by nasal continuous positive airway pressure (ncpap), preterm newborns without at least ncpap pause before 32 6/7 gestational age will be excluded
effectiveness of adding pilates exercises to sports hernia rehabilitation:a comparative clinical trial

Conditions: Pilates Exercises; Sports Hernia

Summary: the study recruited male sports hernias patients referred for physical therapy by an orthopedist or general practitioner from damietta general hospital. participants had to be between 18 and 45 years old, have had sports hernia for two to ten weeks, and be willing and able to attend and stick to the pilates exercise program for the trial's entire duration

the study recruited male sports hernias patients referred for physical therapy by an orthopedist or general practitioner from damietta general hospital. participants had to be between 18 and 45 years old, have had sports hernias for two to ten weeks, and be willing and able to attend and stick to the pilates exercise program for the entire trial. exclusion criteria were applied to patients with preexisting injuries or conditions that could affect pilates exercise participation and those with contraindications or exacerbating conditions from such exercises. further criteria were currently participating in other intensive exercise or rehabilitation programs and inability to give informed consent due to cognitive or communicative issues

Eligibility criteria:
inclusion criteria: * participants had to be between 18 and 45 years old, * have had sports hernia for two to ten weeks * be willing and able to attend and stick to the pilates exercise program for the trial's entire duration exclusion criteria: * patients with preexisting injuries or conditions that could affect pilates exercise participation * those with contraindications or exacerbating conditions from such exercises. * currently participating in other intensive exercise or rehabilitation programs * inability to give informed consent due to cognitive or communicative issues.
use of sentinel cells for the development of molecular tests to control the quality of cryopreservation

Conditions: Aneurysm of the Abdominal Aorta

Summary: the aim is to set up tools that will serve as quality tracers for cryopreservation procedures. to meet this objective, we have chosen to develop reference samples (sentinel cells) that, in the medium term, can be used as controls to guarantee the quality of preservation for biological samples. the biological tools and an optimised follow-up strategy will make it possible to validate preservation procedures at the crb in order to guarantee the perfect stability of samples and the validity of clinical studies.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years * all patients presenting an abdominal aorta diameter of at least 5 cm at the time of discovery and who have surgery exclusion criteria: * patients who do not have aneurysm of the abdominal aorta * refusal to sign the consent form for participation * patients who do not wish to have their operation in dijon or strasbourg chu
an observational study on the impact of insulin resistance on sustained virological response in patients with hepatitis c treated with pegasys (peginterferon alfa-2a) and copegus (ribavirin)

Conditions: Hepatitis C, Chronic

Summary: this prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis c treated with pegasys and copegus. data will be collected from each patient during the up to 72 weeks of treatment and for 24 weeks of treatment-free follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c (detectable hcv rna) * initiation of treatment with pegasys and copegus exclusion criteria: * participation in a clinical trial during the study
management of post dural pucture headache after lower limb surgeries: oral prednisolone vs oral pregabalin

Conditions: Analgesia

Summary: the aim of this study is to compare between oral prednisolone and oral pregabalin in management of pdph to detect effectiveness of the treatment in reducing severity of pdph, total rescue analgesic consumption and adverse effects of prednisolone and pregabalin in patients undergoing lower limb surgery.

1. to compare between oral prednisolone and oral pregabalin in reducing severity post-dural puncture headache after spinal anesthesia in patients undergoing lower limb surgeries. 2. to calculate total amount of postoperative analgesic requirement for 72 hours after the onset of the headache in all patient groups. 3. to detect any side effects of the study medications in all patient groups.

Eligibility criteria:
inclusion criteria: * - both gender. * age: 18- 65 years old. * body mass index 20-30 kg/m2 * american society of anesthesiologist (asa) physical status i - ii. * patients are diagnosed as pdph according to criteria of international headache society (ihs) after lower limb surgeries . exclusion criteria: * - allergy to study drugs. * history of chronic headache and migraine. * history of cerebrovascular accidents and neurological disorders. * systemic infection * history of uncontrolled dm or hepatic disease or pregnant female * patient refusal or uncooperative patient.

Keywords: oral prednisolone oral pregabalin post dural puncture headache (pdph) lower limb surgeries
sex differences in attentional bias in marijuana-dependent individuals

Conditions: Marijuana Dependence

Summary: the purpose of this study is to explore sex differences in cognitive functioning and responses to marijuana-related items, and to determine whether stress impacts these measures. hypothesis 1: attentional bias will be greater for marijuana cues in male marijuana-dependent subjects relative to female marijuana-dependent or non-dependent male controls. hypothesis 2: marijuana-dependent females will exhibit greater stress-induced changes in attentional bias and cognitive functioning than marijuana-dependent males.

ample evidence implicates both environmental cues and negative affective states in maintaining drug use or triggering relapse. however, although 'craving' is believed to drive continued drug use, it is not well understood how cognitive processes influence craving and relapse, nor how they may differ between the sexes. therefore, the goal of this study protocol is to provide insight into sex differences in the cognitive aspects of drug craving and to assess the impact of stress on attentional bias for drug-related cues as well as on the availability of cognitive resources.

Eligibility criteria:
inclusion criteria: * inclusion criteria will include subjects between the ages of 18-65 who meet full dsm-iv criteria for marijuana dependence and non-dependent controls. exclusion criteria: * exclusion criteria will include medications that may affect cognitive or hpa-axis functioning * current depression * bipolar disorder * attention deficit hyperactivity disorder * history of psychosis * suicidal or homicidal intent * significant cognitive deficits * dependence on any substance other than marijuana, nicotine, or caffeine.

Keywords: marijuana dependence cognition stress
evaluation of safety and efficacy of allo gda-201 natural killer (nk) cells in patients with relapsed/refractory b cell nhl

Conditions: Non-Hodgkin Lymphoma

Summary: this is an open-label, non-randomized, interventional, single group assignment study of gda-201, an allogeneic cryopreserved natural killer (nk) cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-cd20 antibody, for patients with relapsed or refractory b cell non-hodgkin lymphoma (nhl).

the study is divided into a phase i dose escalation phase and a phase ii expansion phase. patients with relapsed or refractory follicular lymphoma (fl) or diffuse large b-cell lymphoma (dlbcl)/high grade b-cell lymphoma (hgbcl) will receive gda-201 followed by a short course of low-dose interleukin-2 (il-2). rituximab will be administered prior to and after gda-201 infusion. phase i: dose escalation phase the objective of phase i is to evaluate the safety of gda-201 in patients with fl, dlbcl/ hgbcl, marginal zone lymphoma or mantle cell lymphoma. the maximal tolerated dose (mtd) and recommended phase ii dose (rp2d) will be determined based on dose limiting toxicities (dlt). phase ii expansion phase the objective of the phase ii expansion cohort is to evaluate the safety and efficacy of gda-201 in two patient cohorts, fl and dlbcl/hgbcl.

Eligibility criteria:
inclusion criteria: 1. patients must have relapsed/refractory fl or hgbcl/dlbcl that has failed conventional therapy defined as follows: 1. received at least 2 prior lines of therapy 2. transplant ineligible patients allowed assuming they meet criterion a. 3. patients who received prior chimeric antigen receptor modified t-cells (car-t) cell therapy or are considered ineligible for car-t therapy per the investigator's discretion 4. fl transformed to hgbcl: must have received at least 1 line of therapy after transformation to dlbcl/hgbcl 2. patients must be at least 18 years of age 3. patients must have adequate hematologic, hepatic, renal, cardiac and pulmonary function prior to any study treatment. exclusion criteria: 1. central nervous system (cns) lymphoma 2. time between previous treatment and first dose of study treatment (rituximab): 1. allogeneic hematopoietic stem cell transplantation (hsct) \< 6 months prior to study treatment 2. autologous hsct \< 3 months prior to study treatment 3. car-t \< 2 months prior to study treatment

Keywords: lymphoma gda-201 nk cells rituximab lymphoma, b-cell lymphoma, large b-cell, diffuse
effect of resistance exercise on physical and psychological factors

Conditions: Healthy; Physically Inactive

Summary: physical inactivity is a key risk factor for cardiovascular and metabolic disorders, negatively affecting emotional well-being by increasing psychological distress and reducing mental health. this study aimed to evaluate the impact of a resistance-based physical activity program on physical and psychological outcomes in physically inactive adults.

background/objectives: sedentary behavior is a prevalent risk factor contributing to the development and progression of cardiovascular and metabolic diseases. additionally, physical inactivity has been linked to diminished emotional well-being, characterized by elevated levels of psychological distress and compromised mental health. the present study was designed to investigate the effects of a resistance-focused physical activity intervention on both physical and psychological health outcomes in adults with chronically low levels of physical activity. a randomized controlled trial design was employed. the participant comprised 32 adults (mean age = 46.61 ± 7.33 years) included in the study. these individuals were randomly allocated to either a resistance exercise group (eg, n = 15) or a control group (cg, n = 17). comprehensive assessments were conducted at baseline and following the 12-week intervention. these assessments included evaluations of muscle strength (knee flexors, knee extensors, ankle dorsiflexors, plantar flexors, and core isometric strength), static and dynamic balance, proprioception, and functional movement capacity (as measured by the functional movement screen (fms)). participants' psychological states were quantified using the depression, anxiety, and stress scale-21 (dass-21). the eg participated in a supervised resistance training program 3 days per week for 12 weeks, with each session lasting approximately 55-60 minutes. conversely, the cg did not engage in any structured exercise program and were advised to maintain their customary lifestyle habits throughout the study duration.

Eligibility criteria:
inclusion criteria: * aged between 40-60 years * physically independent * not having cardiac, orthopedic, or musculoskeletal dysfunctions * not participating in regular physical activity more than once a week for the last 5 months before the beginning of the study exclusion criteria: * chronic ankle instability * lower extremity musculoskeletal injury in the previous 6 months * undergoing hormonal replacement therapy * having uncontrolled diabetes * having uncontrolled hypertension * histroy of cardiovascular disease

Keywords: strength balance depression
ziprasidone switching in response to adherence and psychotropic-related weight gain concerns among patients with bipolar disorder (zip ad)

Conditions: Medication Adherence; Bipolar Disorder

Summary: psychotropic-related weight gain is a common concern among patients with bipolar disorder (bd). this concern affects an individual's satisfaction with treatment and may lead to reduced adherence and illness relapse. patient-focused care is attentive to patient concerns while at the same time utilizing evidence-based treatments. ziprasidone is currently fda approved for the maintenance treatment of bd. ziprasidone may be associated with less weight gain compared to some alternative bd maintenance treatments. the proposed project will evaluate how switching to ziprasidone may affect patient adherence, drug attitudes, satisfaction with care and clinical outcomes (psychiatric symptoms, functional status, weight) among bd patients concerned with weight gain.


Eligibility criteria:
inclusion criteria: 1. diagnosis of type i or ii bd for at least 6 months (confirmed with mini) 2. on maintenance evidence-based treatment for bd (lithium, antipsychotic, anticonvulsant) 3. have weight gain concerns that individual believes are related to bd medication treatment 4. sub-optimal adherence as measured by the tablet routines questionnaire (trq) and which the patient feels is related to weight gain concerns. trq threshold will be defined as missing an average of 20% or more of all prescribed bd treatment in the last week or month or missing 20% or more of the "offending agent" in the last week or last month. this is consistent with methodologies in pis previous bd adherence studies exclusion criteria: 1. known resistance or intolerance to ziprasidone 2. medical contraindication to ziprasidone 3. individuals on ziprasidone immediately prior to study enrollment 4. prior or current treatment with clozapine 5. diagnosis of eating disorder 6. individuals whose sub-optimal adherence is related to inability to pay for bd medication treatment or inability to arrange transportation to bd treatment clinical visits 7. concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial 8. current substance dependence 9. high risk of harm to self or others 10. female who is currently pregnant or breastfeeding
pharmacogenetic dosage algorithm for acenocoumarol

Conditions: Atrial Fibrillation; Venous Thromboses; Cardiac Valve Disease

Summary: the use of coumarins has been a challenge for doctors because of its narrow therapeutic range and they show great inter and intra-individual variability in the dose necessary to achieve an international normalized ratio (inr) within the therapeutic range. among the factors influencing the interindividual variability in the dose required include age, weight, vitamin k in the diet, comorbidity as well as drug interactions and in recent years has also seen the importance of pharmacogenetic factors.

demographic and clinical factors contribute approximately 20% to the total variability of dose requirements. in recent years it has highlighted the close relationship between the dose requirements of coumarin drugs and certain polymorphisms of genes involved in pharmacokinetics and pharmacodynamics of these drugs. the use of dosing algorithms that include pharmacogenetic information may help in the dose selection, improving efficacy and reducing adverse events. studies have shown the relationship between genotype variants of cyp2c9 and vkorc1, cyp4f2 and apolipoprotein e (apoe), which together with the demographic and clinical variants can explain between 50-60% of the variability in the response to these drugs.

Eligibility criteria:
inclusion criteria: * patients with auricular fibrillation, venous thromboembolic disease and cardiac valve replacement receiving acenocoumarol. * patients with stable dose of acenocoumarol (weekly dose variation of \<20% in the last 3 months). * patients with an international normalised ratio within the range of 2 to 3 (in auricular fibrillation and venous thromboembolic disease) or 2.5 to 3.5 (in cardiac valve replacement) for at least the 3 previous consecutive months. exclusion criteria: * patients with renal failure (calculated creatinine clearance ≤30 ml/min), hepatic disease (stage c of child plough stage), thyroid dysfunction and/or cancer.

Keywords: acenocoumarol cytochrome p450 pharmacogenetics algorithm cyp2c9 vkorc1 cyp4f2 p450 oxidoreductase (por)
lidocaine patch for treatment of persistent inguinal postherniorrhaphy pain

Conditions: Inguinal Pain

Summary: in the present placebo-controlled cross-over study the researchers intend to investigate analgesic and sensory effects of a lidocaine patch in patients with severe persistent inguinal post-herniorrhaphy pain.


Eligibility criteria:
inclusion criteria: * males \> 18 yrs * asa (american society´s of anesthesiology´s classification) scores i-iii, with severe pain for more than six months and with average daily pain intensities (numerical rating scale \[nrs\] 0-10 points) during rest or during movement \> 6. exclusion criteria: * history of an allergic reaction or intolerance to amide local anesthetics or vehicle ingredients in the patches * use of class i antiarrhythmic drugs (e.g., tocainide and mexiletine) * severe cardiac impairment, e.g., nyha (new york heart association) class ≥ iii * inflamed or injured skin at the application site * known severe hepatic disorder (child-pugh score \> 6) * known severe renal impairment, (creatinine clearance \< 30 ml/min) * signs of cognitive impairment or known drug or ethanol abuse during the last 2 years.

Keywords: persistent postherniorrhaphy inguinal pain